Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

OBJECTIVES: Based on data from clinical practice, we evaluated the effectiveness and safety of switching to abacavir/lamivudine plus rilpivirine (ABC/3TC+RPV) treatment in virologically suppressed HIV-1-infected patients. METHODS: We performed a multicenter, non-controlled, retrospective study of HI...

Descripción completa

Detalles Bibliográficos
Autores principales: Troya, Jesús, Ryan, Pablo, Ribera, Esteban, Podzamczer, Daniel, Hontañón, Victor, Terrón, Jose Alberto, Boix, Vicente, Moreno, Santiago, Barrufet, Pilar, Castaño, Manuel, Carrero, Ana, Galindo, María José, Suárez-Lozano, Ignacio, Knobel, Hernando, Raffo, Miguel, Solís, Javier, Yllescas, María, Esteban, Herminia, González-García, Juan, Berenguer, Juan, Imaz, Arkaitz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058546/
https://www.ncbi.nlm.nih.gov/pubmed/27727331
http://dx.doi.org/10.1371/journal.pone.0164455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058546/
https://www.ncbi.nlm.nih.gov/pubmed/27727331
http://dx.doi.org/10.1371/journal.pone.0164455

Ejemplares similares